Ignite Creation Date:
2024-05-06 @ 9:58 AM
Last Modification Date:
2024-10-26 @ 12:22 PM
Study NCT ID:
NCT03123783
Status:
COMPLETED
Last Update Posted:
2023-12-26
First Post:
2017-04-17
Brief Title:
CD40 Agonistic Antibody APX005M Sotigalimab in Combination With Nivolumab
Sponsor:
Apexigen America Inc
Organization:
Apexigen America Inc
Organization Data
Organization:
Apexigen America Inc
Class:
INDUSTRY
Study ID:
APX005M-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Apexigen America Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |